You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 80 Next »

Project Scope

  • Define role of QTLs in QbD, in particular the relationship to CTQs (Critical to Quality Factors), Estimands and continuous quality improvement (CQI)
  • Discuss the use of QTLs in Early Development/small studies, bio equivalence and complex designs
  • Discuss examples of how to define QTLs, different methodologies and different parameters in use across the industry
  • Discuss difficulties and challenges of implementation of QTLs
  • Examine role of QTLs as part of the of the lessons learned (RCA) feedback loop
Project LeadsEmail
Michael Walega (Bristol Myers Squibb)michael.walega@bms.com
Chris Wells (Roche)chris.wells.cw1@roche.com
Lauren White (PHUSE Project Coordinator) 

lauren@phuse.global 

Objectives & DeliverablesTimelines
Release of draft White Paper Q3 2022
Publish White PaperQ3 2023

CURRENT STATUS Q1 2023

Evaluation of survey results. Development of white paper with the goal of publishing in Q3 2023
Project MembersOrganisation
Alicja MarkGenmab
Andrew McGowanRHO World
Andrzej KinasiewiczAstraZeneca
Anne LawrenceAbbVie
Ansalan StewartFDA
Arati TodkarTCS
Barbara SeiderZealand Pharma 
Chonna CampbellUnither Pharmaceuticals
Crupa KurienPfizer
Debra JendrasekDSI
Heidi HoffmanGenentech
Jennifer KrohnPPD
Jean MulindeFDA
Julie AppelNovo Nordisk
Karen BleichFDA
Kate TomlinsonPRISM
Katherine TaylorMerck
Kevin DouglassDSI
Kingsley KaluarachchiGE HealthCare 
Linda Del PaggioGenentech
Lukasz BojarskiAstraZeneca
Lynne CesarioPfizer
Mary ArnouldAstellas
Project MembersOrganisation
Mireille LovejoyRoche
Monika MoerschBoehringer-Ingelheim
Mukesh BabuIndustry
Nathalie Van BorrendamJanssen Research & Development 
Nick Wells Syneos Health 
Paul BrownDanish Medicines Agency
Priti GuptaPfizer
Shalaka GadhaveTCS
Sheetal ChandaranaRoche
Steve Young CluePoints
Steven GilbertPfizer

Problem Statement

QTLs -  the role they play in defining quality within the QbD framework, their relationship to Critical to Quality factors, associated methodologies and the interpretation of them have not been fully defined in clinical development, in particular where early development/small studies, bio equivalence studies and complex designs are concerned.

Problem Impact

This will impact the whole clinical development process and allow the move away from perfection to a defined and achievable quality, from which continuous quality improvement can begin.

Terminology Example:

  • Target Product Profile (TPP)
    • Patient wants extended dosing from current BD product on market
  • Critical Quality Attribute (CQA)
    • Once a day dosing
  • Critical to Quality Factor (CTQ)
    • In early stage trials drug levels shown at 24 hours
    • In Phase 2-3 demonstrate efficacy
  • Quality Tolerance Limit
    • Pre-define what will be acceptable limits for acceptance
      • These QTL's will change at different stages




  • No labels